STAT+: In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages
Doctors have been eagerly waiting for data on Guardant Health’s new blood-based colorectal cancer screening…
Category: STAT+
STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies
In a setback to the pharmaceutical industry, a U.S. appeals court has upheld an Arkansas…
STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: AI health care companies say they’ll keep humans in the loop. But what does that actually mean?
Developers of artificial intelligence models slowly making their way into medicine have long parried ethical…
STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?
As a boy growing up with hemophilia A, Noah Frederick reserved the end of his…
.jpg)
STAT+: “It’s a bit chaotic”: Hospitals struggle to validate AI-generated clinical summaries
Rob Bart remembers what it felt like, the moment of discovery. As an intern at…
STAT+: Here’s what you might have missed in Biden’s budget proposal
WASHINGTON — President Biden on Monday unveiled his requests for the 2025 budget, potentially his…
STAT+: For-profit health system’s Mass. hospitals teetering on the brink of financial disaster
Steward Health Care’s Massachusetts hospitals are on the brink of financial disaster. But in many…
STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more
Top of the morning to you, and a fine one it is. Sunny skies and…
STAT+: First medicine developed to treat MASH expected to be approved soon
The Food and Drug Administration is expected to approve the first medicine developed specifically to…
STAT+: New methadone rules are about to take effect. Here are 6 ways treatment could shift
The federal government is reforming methadone care for the first time in over two decades….
STAT+: Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study
Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social…
STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: U.K. researchers warn about biases in medical devices, health care algorithms
LONDON — Regulators, clinicians, and health care algorithm developers need to take additional steps to…
STAT+: UnitedHealth is on a buying spree of outpatient surgery centers
UnitedHealth Group quietly acquired dozens of outpatient facilities in 2023, with a particular focus on…
STAT+: Medicare announces loan program to aid providers affected by Change cyberattack
Medicare announced on Saturday that it will make advance payments available to physician groups, hospitals,…
STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next
The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians,…
STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label
U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its…
STAT+: UnitedHealth gives timeline for Change restoration: payments up by late next week
Change Healthcare’s parent company said it’ll have its electronic payment function up and running by…
STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug
In a surprise move, the Food and Drug Administration has called for a meeting of…
STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone
If you’re a drug company executive, you probably feel like you got up on the…
Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development
In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed…
STAT+: Pharma giants, government spar in court over Medicare drug price negotiation
TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson and Johnson, Novartis, and…
STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more
Rise and shine, everyone, another busy day is on the way. Moreover, this is shaping…
STAT+: Former medical device CEO who sold dummy, plastic parts convicted of fraud
A New York jury on Wednesday convicted the former CEO of Stimwave, a company that…
STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial
A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss…
STAT+: Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35
Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a…
STAT+: Nursing home owners can hide nearly two-thirds of their profits, new study shows
A new study shows that some nursing homes are shunting the majority of their profits…
STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
.jpg)
STAT+: Senate panel advances bill to ban some Chinese biotechs, with Sen. Paul taking up industry’s cause
WASHINGTON — A Senate panel today passed a bill aimed at preventing certain Chinese companies…
STAT+: Pharmalittle: We’re reading about HIV drug resistance, march-in rights, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
Startup Alumis raises $259 million as it prepares for psoriasis trial
San Francisco startup Alumis Inc. has raised $259 million in a bid to best big…
STAT+: With Meta’s backing, Headspace launches into VR
Headspace, which has built a growing digital health business around mindfulness, is joining forces with…
STAT+: Republicans consider a new attack on Biden ‘march-in’ plan for lower drug prices
WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the…
STAT+: Oracle Health chair says Cerner isn’t competing with Epic
Cerner may have ceded U.S. business to reigning electronic health records market leader Epic Systems,…
STAT+: FDA clears first over-the-counter continuous glucose monitor
For the first time, anyone in the United States will soon be able to buy…
STAT+: Large insurers say up to one-quarter of claims run through Change Healthcare
Some of the country’s biggest health insurers said Tuesday that up to one-quarter of their…
STAT+: Harvard longevity scientist sparks furor with claim about reversing aging in dogs
Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists…
STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned
After 18 months of debate, the World Trade Organization failed to adopt a controversial proposal…
STAT+: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more
Good morning, everyone, and how are you today? We are doing just fine, despite a…
STAT+: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows
LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney…
STAT+: Q&A: Nora Volkow on how to get ‘at least 50% less people dying’ from opioid overdose
In 2003, the year Nora Volkow was appointed director of the National Institute on Drug…
STAT+: White House is told the big three PBMs are ‘everything wrong with this industry’
As part of its battle to blunt the growing cost of medicines, the White House…
STAT+: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling
A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and…
STAT+: White House touts incremental step in Medicare drug price negotiation: counteroffers
WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program…
STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: He’s 19 months old and has one of the world’s rarest diseases. His parents are determined to find a cure.
SOMERVILLE — At 19 months old, Lucas Guo has never crawled, walked, or stood by…
STAT+: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows
Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease…
STAT+: Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards
At first glance, the Coalition for Health AI looks like any technology lobbying group. Its…